Mylan Laboratories Ltd. v. Janssen Pharmaceutica
Petition for certiorari denied on January 18, 2022
Issues: (1) Whether 35 U.S.C. § 314(d) categorically precludes appeal of all decisions not to institute inter partes review; and (2) whether the NHK-Fintiv Rule is substantively and procedurally unlawful.
| Date | Proceedings and Orders (key to color coding) |
|---|
| Aug 09 2021 | Petition for a writ of certiorari filed. (Response due September 13, 2021) |
| Aug 18 2021 | Motion to extend the time to file a response from September 13, 2021 to October 12, 2021, submitted to The Clerk. |
| Aug 19 2021 | Motion to extend the time to file a response is granted and the time is extended to and including October 12, 2021, for all respondents. |
| Aug 25 2021 | Brief amicus curiae of Jeremy C. Doerre in support of neither party filed. |
| Sep 13 2021 | Brief amicus curiae of Association for Accessible Medicines filed. |
| Sep 13 2021 | Brief amicus curiae of Intel Corporation filed. |
| Sep 30 2021 | Motion to extend the time to file a response from October 12, 2021 to November 2, 2021, submitted to The Clerk. |
| Oct 01 2021 | Motion to extend the time to file a response is granted and the time is further extended to and including November 2, 2021, for all respondents. |
| Nov 02 2021 | Brief of Federal Respondent in opposition filed. |
| Nov 02 2021 | Brief of respondent Janssen Pharmaceutica NV in opposition filed. |
| Nov 16 2021 | DISTRIBUTED for Conference of 12/3/2021. |
| Nov 16 2021 | Reply of petitioner Mylan Laboratories Ltd. filed. (Distributed) |
| Nov 23 2021 | Rescheduled. |
| Dec 29 2021 | DISTRIBUTED for Conference of 1/14/2022. |
| Jan 18 2022 | Petition DENIED. Justice Alito took no part in the consideration or decision of this petition. |
